-Bloomberg
Synlogic’s Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients
Synlogic Inc's (NASDAQ: SYBX) SYNB8802 has demonstrated proof of concept through a clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.